Pharmaceuticals News and Research

RSS

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

Otsuka Pharmaceutical Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted the submission of a marketing authorisation application (MAA) for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

27 Dec 2013

Oral ingestion of inosine compound raises urate levels, shows Parkinson's study

New findings published in JAMA Neurology from research into a potentially protective therapy for Parkinson's disease (PD) show that with medical supervision, urate levels may safely be raised while mitigating risk of complications such as gout.

27 Dec 2013

Teva Pharmaceuticals sells 31 generic drug products to ANI Pharmaceuticals

ANI Pharmaceuticals, Inc., an emerging generic pharmaceutical company, today announced that it has acquired 31 previously marketed generic drug products from Teva Pharmaceuticals for $12.5 million in cash and a percentage of future gross profits from product sales.

27 Dec 2013

Scientists find inhibiting action of BRD4 protein may eradicate rare type of soft-tissue cancer

A deadly, rare type of soft-tissue cancer may be completely eradicated simply by inhibiting a key protein involved in its growth, UT Southwestern Medical Center researchers report.

27 Dec 2013

Oramed Pharmaceuticals to purchase $15,800,000 shares in registered direct offering

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, today announced that it has entered into definitive agreements with investors to purchase an aggregate of 1,580,000 shares of common stock at a price of $10.00 per share in a registered direct offering.

26 Dec 2013

Taro declares preliminary results of modified tender to repurchase $200M shares

Taro Pharmaceutical Industries Ltd.("Taro" or the "Company") today announced the preliminary results of its modified "Dutch auction" tender offer to repurchase up to $200 million in value of its ordinary shares, which expired at 12:00 midnight, New York City time, on Monday, December 23, 2013.

26 Dec 2013

FDA extends PDUFA Priority Review action date for UC indication of Takeda's vedolizumab

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food & Drug Administration has extended the Prescription Drug User Fee Act Priority Review action date for the ulcerative colitis indication of Takeda's investigational biologic, vedolizumab.

24 Dec 2013

Synergy Pharmaceuticals closes patient enrollment in plecanatide phase 2b clinical trial in IBS-C

Synergy Pharmaceuticals Inc. today announced it has closed patient enrollment in its plecanatide phase 2b clinical trial in irritable bowel syndrome with constipation.

24 Dec 2013

Concordia Healthcare acquires Pinnacle Biologics

Concordia Healthcare Corp., an integrated, specialty healthcare company focused on the acquisition of legacy pharmaceutical products and medical devices and the acquisition and/or development of orphan drugs, announced today that it has acquired Pinnacle Biologics, Inc., a U.S.-based biopharmaceutical company specializing in legacy pharmaceuticals which have the potential for development as orphan drugs to treat cancer indications in addition to those for which they have previously been approved.

24 Dec 2013

U.S. FDA grants Veloxis Orphan Drug status for Envarsus

Veloxis Pharmaceuticals A/S, today announced that Envarsus was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients receiving allogenic kidney transplants.

24 Dec 2013

New tools for neglected diseases: an interview with Dr. BT Slingsby, CEO, GHIT Fund

Nearly 3.3 billion people, a little less than half of our world’s population, are at risk of malaria, TB and what we call “neglected tropical diseases”—diseases caused by worms, parasites, viruses and bacteria like Chagas disease, river blindness, elephantiasis, sleeping sickness, etc.

24 Dec 2013

Reflux disease diagnosis: an interview with Professor Peter Dettmar, Managing Director of RD Biomed Limited

Generally speaking, reflux has been a major chronic issue for probably the last 40 or 50 years. When you look at the global population, depending on which country we're talking about, around 20% to 40% of individuals have reflux disease within their populations.

23 Dec 2013

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

Antisense Therapeutics Limited is pleased to advise that positive results have been achieved from the interim analysis of a subset of available data from its Phase II clinical trial of ATL1103 in patients with the growth disorder, acromegaly.

23 Dec 2013

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Merck Serono, the biopharmaceutical division of Merck, today announced that the European Commission has approved the Type II variation to amend the Erbitux(cetuximab) product information, updating the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC).

23 Dec 2013

Researchers compare prescription drug costs between the U.S. and the U.K

The 2009 costs of antibiotics covered by private insurance companies in the U.S. for children younger than 10 years old were estimated to be more than five times higher than the costs in the United Kingdom (U.K.), which are covered by a government universal health plan.

23 Dec 2013

TSRI scientists identify compound that shows promise for treating obesity-linked diabetes

Scientists at The Scripps Research Institute (TSRI) have demonstrated a drug-discovery strategy with a double payoff-it enables the rapid selection of chemical compounds that have a desired effect on cells and also highlights how the compounds work.

23 Dec 2013

Key questions to ask about bone marrow transplants

Those who have leukemia, lymphoma or other blood cancer diseases might have heard about bone marrow transplant as a potential treatment. As with any serious procedure, it is important to have all questions answered by a physician before any decision is made.

20 Dec 2013

Biocryst seeks FDA NDA approval for Peramivir to treat influenza

BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.

20 Dec 2013

Walgreen's net earnings increase $695M to 68.3% in fiscal 2014 first quarter

Walgreen Co. today announced earnings and sales results for the first quarter of fiscal year 2014 ended Nov. 30. Net earnings determined in accordance with generally accepted accounting principles (GAAP) for the fiscal 2014 first quarter were $695 million, a 68.3 percent increase from $413 million in the year-ago quarter.

20 Dec 2013

Oramed reports positive results from ORMD-0801 pharmacokinetic study in type 1 diabetes patients

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today successful results in a clinical trial testing the pharmacokinetic dose response of its oral insulin capsule (ORMD-0801) in type 1 diabetes patients.

20 Dec 2013

Pharmaceuticals News and Research

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

Oral ingestion of inosine compound raises urate levels, shows Parkinson's study

Teva Pharmaceuticals sells 31 generic drug products to ANI Pharmaceuticals

Scientists find inhibiting action of BRD4 protein may eradicate rare type of soft-tissue cancer

Oramed Pharmaceuticals to purchase $15,800,000 shares in registered direct offering

Taro declares preliminary results of modified tender to repurchase $200M shares

FDA extends PDUFA Priority Review action date for UC indication of Takeda's vedolizumab

Synergy Pharmaceuticals closes patient enrollment in plecanatide phase 2b clinical trial in IBS-C

Concordia Healthcare acquires Pinnacle Biologics

U.S. FDA grants Veloxis Orphan Drug status for Envarsus

New tools for neglected diseases: an interview with Dr. BT Slingsby, CEO, GHIT Fund

Reflux disease diagnosis: an interview with Professor Peter Dettmar, Managing Director of RD Biomed Limited

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Researchers compare prescription drug costs between the U.S. and the U.K

TSRI scientists identify compound that shows promise for treating obesity-linked diabetes

Key questions to ask about bone marrow transplants

Biocryst seeks FDA NDA approval for Peramivir to treat influenza

Walgreen's net earnings increase $695M to 68.3% in fiscal 2014 first quarter

Oramed reports positive results from ORMD-0801 pharmacokinetic study in type 1 diabetes patients

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence